BR112015024110A2 - método de detecção de um distúrbio de gravidez ou aneuploidia fetal até o segundo trimestre - Google Patents

método de detecção de um distúrbio de gravidez ou aneuploidia fetal até o segundo trimestre

Info

Publication number
BR112015024110A2
BR112015024110A2 BR112015024110A BR112015024110A BR112015024110A2 BR 112015024110 A2 BR112015024110 A2 BR 112015024110A2 BR 112015024110 A BR112015024110 A BR 112015024110A BR 112015024110 A BR112015024110 A BR 112015024110A BR 112015024110 A2 BR112015024110 A2 BR 112015024110A2
Authority
BR
Brazil
Prior art keywords
trimester
detecting
fetal
fetal aneuploidy
pregnancy
Prior art date
Application number
BR112015024110A
Other languages
English (en)
Inventor
Kruse Iles Raymond
Andrew Butler Stephen
Original Assignee
Map Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Map Diagnostics Ltd filed Critical Map Diagnostics Ltd
Publication of BR112015024110A2 publication Critical patent/BR112015024110A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0027—Methods for using particle spectrometers
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/26—Mass spectrometers or separator tubes
    • H01J49/34—Dynamic spectrometers
    • H01J49/40—Time-of-flight spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

resumo método de detecção de um distúrbio de gravidez ou aneuploidia fetal até o segundo trimestre a presente invenção refere-se a um método de triagem de amostras de urina maternas para alterações no padrão de impressão digital de espectro de massa que foram observadas como características de aneuploidias fetais tal como síndrome de down e tem aplicação na triagem de outras anormalidades e distúrbios fetais de gravidez que incluem doenças trofoblásticas gestacionais. 1/1
BR112015024110A 2013-03-22 2014-03-20 método de detecção de um distúrbio de gravidez ou aneuploidia fetal até o segundo trimestre BR112015024110A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1305317.8A GB201305317D0 (en) 2013-03-22 2013-03-22 Prenatal screening for fetal abnormalities and disorders of pregnancy
PCT/GB2014/050876 WO2014147404A1 (en) 2013-03-22 2014-03-20 Prenatal screening

Publications (1)

Publication Number Publication Date
BR112015024110A2 true BR112015024110A2 (pt) 2017-07-18

Family

ID=48326524

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015024110A BR112015024110A2 (pt) 2013-03-22 2014-03-20 método de detecção de um distúrbio de gravidez ou aneuploidia fetal até o segundo trimestre

Country Status (11)

Country Link
US (1) US10393729B2 (pt)
EP (1) EP2976647B1 (pt)
JP (1) JP6441892B2 (pt)
CN (1) CN105452868B (pt)
AU (1) AU2014234010A1 (pt)
BR (1) BR112015024110A2 (pt)
CA (1) CA2900333A1 (pt)
EA (1) EA201591682A1 (pt)
GB (2) GB201305317D0 (pt)
HK (3) HK1214358A1 (pt)
WO (1) WO2014147404A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2943778B1 (en) 2013-01-09 2020-10-28 The Regents of The University of California Apparatus and methods for fluorescence imaging using radiofrequency-multiplexed excitation
EP3120130B1 (en) 2014-03-18 2023-07-26 The Regents of the University of California Parallel flow cytometer using radiofrequency mulitplexing, and method
EP3362778B1 (en) 2015-10-13 2022-08-03 Omega Biosystems Incorporated Multi-modal fluorescence imaging flow cytometry system
AU2017234815B2 (en) 2016-03-17 2022-11-03 Becton, Dickinson And Company Cell sorting using a high throughput fluorescence flow cytometer
EP3455608A1 (en) * 2016-05-12 2019-03-20 BD Biosciences Fluorescence imaging flow cytometry with enhanced image resolution
CN109477785B (zh) 2016-09-13 2022-09-27 贝克顿·迪金森公司 具有光学均衡的流式细胞仪
DE102017008885B4 (de) 2017-09-22 2024-04-25 Bruker Daltonics GmbH & Co. KG Massenspektrometrisches Verfahren und MALDI-TOF-Massenspektrometer
DE102018103609B4 (de) 2018-02-19 2021-06-02 Bruker Daltonik Gmbh Flüssigkeitsanschluss-Einrichtung für die Ionisierung durch Elektrosprühen
CN111202492B (zh) * 2018-11-20 2021-08-10 中国科学院上海营养与健康研究所 基于机器学习算法搭建的唐氏综合征肤纹辅助筛查
CN110808099B (zh) * 2019-03-27 2021-01-26 北京大学第三医院（北京大学第三临床医学院） 一种用于检测异位妊娠的系统
WO2021007075A1 (en) 2019-07-10 2021-01-14 Becton, Dickinson And Company Reconfigurable integrated circuits for adjusting cell sorting classification

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324667A (en) * 1989-01-17 1994-06-28 Macri James N Method for detecting down sydrown by non-invasive maternal blood screening
US5716853A (en) * 1995-07-07 1998-02-10 Chiron Diagnostics Corporation Prenatal down syndrome screening with assays specific for UGP
WO2003065043A2 (en) 2002-01-29 2003-08-07 King's College London An Institute Incorporated By Royal Charter Of Strand Identification and relative quantification of proteins
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
US8068990B2 (en) * 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
US7425700B2 (en) * 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
US7991557B2 (en) * 2004-06-19 2011-08-02 Genenews Corporation Computer system and methods for constructing biological classifiers and uses thereof
JP2008513031A (ja) * 2004-09-20 2008-05-01 プロテオジェニックス， インコーポレイテッド 胎児異数性の診断
CA2608988A1 (en) * 2005-06-03 2006-12-07 Cambridge Enterprise Limited Biomarkers for psychotic disorders
CN100410663C (zh) * 2005-09-11 2008-08-13 翁炳焕 蛋白质组的分析方法
WO2009059259A2 (en) * 2007-10-31 2009-05-07 Children's Hospital Medical Center Detection of worsening renal disease in subjects with systemic lupus erythematosus
JP2012093230A (ja) * 2010-10-27 2012-05-17 St Marianna Univ School Of Medicine Ｃ型肝炎に対するペグインターフェロン・リバビリン併用療法の治療効果の予測方法およびそれに用いられる予測キット
EP2836833A4 (en) * 2012-04-13 2015-10-14 Univ Wayne State PRENATAL DETECTION OF DOWN SYNDROME AND TRISOMY 18

Also Published As

Publication number Publication date
JP2016518591A (ja) 2016-06-23
JP6441892B2 (ja) 2018-12-19
US10393729B2 (en) 2019-08-27
EA201591682A1 (ru) 2016-02-29
CN105452868B (zh) 2019-04-19
CA2900333A1 (en) 2014-09-25
EP2976647B1 (en) 2019-05-15
US20160054293A1 (en) 2016-02-25
WO2014147404A1 (en) 2014-09-25
HK1214358A1 (zh) 2016-07-22
HK1221767A1 (zh) 2017-06-09
CN105452868A (zh) 2016-03-30
GB201518627D0 (en) 2015-12-02
AU2014234010A1 (en) 2015-08-20
HK1221768A1 (zh) 2017-06-09
EP2976647A1 (en) 2016-01-27
GB201305317D0 (en) 2013-05-08
GB2531938A (en) 2016-05-04

Similar Documents

Publication Publication Date Title
BR112015024110A2 (pt) método de detecção de um distúrbio de gravidez ou aneuploidia fetal até o segundo trimestre
BR112012018458A2 (pt) métodos e composições para diagnóstico pré-natal não invasivo de aneuploidias fetais
WO2014165267A3 (en) Systems and methods for prenatal genetic analysis
HK1206792A1 (en) Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
BR112013025859A2 (pt) método para a produção de elementos absorventes que têm um perfil de densidade
BR112015022821A2 (pt) método para avaliar status renal em um indivíduo e kit de ensaio de diagnóstico
BR112018008532A2 (pt) detecção de aneuploidias cromossômicas do feto usando regiões de dna que são metiladas de forma diferenciada entre o feto e a mulher grávida
BR112015026660B8 (pt) Ligas metálicas aperfeiçoadas para dispositivos médicos
BR112014026661A2 (pt) método in vitro para diagnóstico e vigilância do câncer
BR112014025520A2 (pt) método para estimar características de uma formação
BR112015016275A2 (pt) previsão com base em modelo em um banco de filtros criticamente amostrado
BR112013026482A2 (pt) captura de amostra em uma única etapa para tiras de teste
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
MX2015010174A (es) Herramientas de diagnostico para predecir la presentacion de preeclampsia.
BR112015012976A2 (pt) método e dispositivo para decodificar sinal
BR112012032389A2 (pt) biomarcadores para a previsão de câncer incidente
BR112014009223A8 (pt) método para o diagnóstico da doença de niemann-pick
BR112015028619A2 (pt) método para medição de nivelamento de material de chapa, dispositivo para medição de nivelamento de material de chapa e método de produção de chapa de aço
BR112015005059A2 (pt) avaliador de composição automatizado
BR112015027249A2 (pt) método de diagnóstico de câncer
IN2014DN08398A (pt)
WO2014155105A3 (en) Assessment of risk of aneuploidy
BR112014025972A8 (pt) monocloridratos de anamorelina, composições, processo para preparar monocloridrato de anamorelina, método para produzir uma forma de dosagem farmacêutica e forma de dosagem farmacêutica oral
EA201691168A1 (ru) Способы исследования бета-глюкана
WO2014169011A3 (en) Methods for treating immune diseases

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MAP IP HOLDING LIMITED (GB)

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2506 DE 15-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.